Skip to main content
Fig. 6 | Cancer Nanotechnology

Fig. 6

From: Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model

Fig. 6

Effect of Afa in various formulations on the cytotoxicity of PC9 cells and the barrier integrity of the BBB model. A Schematic of Afa across the BBB model; B relative cell viability (%) of Afa, Afa/LPN, and peptide-modified LPN across the BBB on PC9 cells. PC9 cells were treated with Afa, Afa/LPN, Afa/LPN-FD7, and Afa/LPN-CCD with or without the BBB for 48 h. Cell viability was measured via SRB assay. Values are the mean ± S.D. (n = 3). *p < 0.05 compared with the control (CTR), p < 0.05 compared with Afa, p < 0.05 compared with Afa/LPN, and §p < 0.05 compared with Afa/LPN-FD7 through Student’s t-test analysis. C Protein expression levels of apoptosis, including Bax, Bcl-2, and caspase 3, and necroptosis such as RIP1 and 3 were detected with Western blot after the above treatment in PC9 cells

Back to article page